Kaken Pharmaceutical
Basic Information
- Stock Code
- 4521
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Tokyo
- Establishment Year
- March 1948
- Listing Year
- October 1961
- Official Website
- http://www.kaken.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Nippon Shinyaku, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Mochida Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Otsuka Holdings
Overview
Kaken Pharmaceutical is a mid-sized pharmaceutical company founded in 1948, a leading industry player primarily focused on joint function improvement agents while engaging in a wide range of pharmaceuticals, agricultural chemicals, and veterinary drugs.
Current Situation
Kaken Pharmaceutical is a steadily growing company with consolidated sales of approximately 98 billion yen and operating profit of about 27 billion yen. It has strengths in the orthopedic field, including its mainstay joint function improvement agents and atherosclerosis treatment drugs, and has established a stable position in the medical pharmaceutical market. It is also expanding in agricultural chemicals and veterinary drugs, characterized by diversified business operations. It leverages its unique technological capabilities in product development, succeeding in obtaining approvals for new drugs and developing therapeutic artificial proteins. It is proactive in environmental considerations and regional collaboration, having signed an agreement with Fujieda City in Shizuoka Prefecture to extend healthy life expectancy. In the medium to long term, it is promoting active technological innovation and sustainability, strengthening its business foundation toward 2030. Caution is needed regarding intensifying competition in domestic and international pharmaceutical markets and regulatory changes, but it aims for sustainable growth through a stable financial base and diversified management.
Trivia
Interesting Facts
- Pharmaceutical company rooted in RIKEN (Institute of Physical and Chemical Research)
- Maintains top domestic share in joint function improvement agents
- Early entry into agricultural chemicals and veterinary pharmaceuticals
- One of the few diversified pharmaceutical manufacturers in Japan
- Operates comprehensive research institutes in Kyoto and Shizuoka
- Also engages in medical device business with proprietary technology
- Signed agreement with Fujieda City on healthy life expectancy extension
- Major shareholders include Toray and Norinchukin Bank
- Mid-sized company with approximately 1,400 employees as of 2018
- Gaining attention for development of therapeutic artificial proteins
- One origin is Yamanouchi Pharmaceutical (now part of Takeda Group)
- Active company in linking medical devices and pharmaceuticals
- Track record in manufacturing diverse pharmaceuticals via OEM
- Corporate philosophy of 'Contributing to medicine and agriculture'
- Also operates rental real estate for business stability
Hidden Connections
- Deep historical capital ties with Yamanouchi Pharmaceutical (now Astellas Pharma)
- Toray maintains capital relationship as major shareholder
- Strong network with local agricultural cooperatives in agricultural chemicals
- Strengthened regional contributions via official agreement with Fujieda City on healthy life expectancy
- Therapeutic artificial protein is a key future technology in regenerative medicine
- Has joint research and supply contracts with multiple pharmaceutical companies
- Feed additive products have good reputation in livestock industry
- Deep transaction relationships with surgical medical institutions for medical injections
Future Outlook
Growth Drivers
- Expansion of joint disease market due to aging population
- Bio-pharma innovations like artificial proteins
- Increasing demand for environmentally adapted agricultural chemical products
- Growth in veterinary pharmaceutical market
- New drug development from regulatory easing and medical technology innovations
- Expansion of community-based healthy life expectancy extension services
- Successful development of medical device-linked products domestically and internationally
- Advancement of digital transformation
- Strengthening of global procurement and sales networks
- Expansion of sustainable manufacturing processes
Strategic Goals
- Expand domestic share in joint function improvement drugs
- Establish artificial protein formulations in pharmaceutical market
- Build environmentally considerate product lines for agricultural chemicals
- Strengthen revenue base in veterinary pharmaceuticals
- Double biopharmaceutical development and manufacturing capacity
- Achieve sustainable manufacturing and logistics systems
- Provide total solutions through integration with medical devices
- Establish healthy life expectancy extension model through regional collaboration
- Achieve 20% of sales from international expansion
- Strengthen corporate culture through talent development and diversity promotion
Business Segments
Medical Pharmaceutical Supply
- Overview
- Manufactures and sells medical pharmaceuticals for orthopedics and circulatory systems.
- Competitiveness
- Pharmaceutical development focused on specialized fields
- Customers
-
- Hospitals
- Clinics
- Pharmacies
- Medical Wholesalers
- Pharmaceutical Companies
- Products
-
- Joint Function Improvement Agents
- Atherosclerosis Treatment Drugs
- Artificial Protein Formulations
- Injections
Agricultural Chemical Provision
- Overview
- Provides high-performance agricultural chemicals for crop protection.
- Competitiveness
- Formulation technology tailored to agricultural sites
- Customers
-
- Agricultural Cooperatives
- Agricultural Material Wholesalers
- Agricultural Corporations
- Local Governments
- Products
-
- Insecticides
- Herbicides
- Fungicides
- Raw Materials
Veterinary Pharmaceuticals & Feed Additives
- Overview
- Supplies health maintenance products for livestock and pets.
- Competitiveness
- Product lineup covering both livestock and pets
- Customers
-
- Veterinary Hospitals
- Livestock Producers
- Pet Shops
- Products
-
- Antibiotics
- Vitamin Additives
- Supplements
Medical Device Sales
- Overview
- Engages in wholesale and direct sales of medical devices.
- Competitiveness
- Product provision linked with pharmaceuticals
- Customers
-
- Hospitals
- Surgical Clinics
- Nursing Homes
- Products
-
- Bandages & Fixation Devices
- Medical Consumables
Competitive Advantage
Strengths
- High R&D capabilities specialized in specific fields
- Stable financial base and long history
- Diversified expansion in pharmaceuticals, agriculture, and veterinary products
- Robust domestic sales channels and customer base
- Collaboration with advanced medical device development
Competitive Advantages
- Market superiority and brand power in joint function improvement agents
- Technological innovation from approval of therapeutic artificial proteins
- Unique technology in agricultural chemicals and site-specific product development
- Business risk diversification through veterinary pharmaceuticals
- Comprehensive medical solutions via linkage with medical devices
Threats
- Intensifying competition with major pharmaceutical companies
- Revenue pressure risk from drug price revisions
- Impact of strengthened regulations or approval delays
- Market share expansion by new entrants
- Strengthened environmental regulations in agriculture
- Supply-demand fluctuations due to pandemics or social impacts
- Risk of international raw material price fluctuations
- Intellectual property infringement risks
- Competition from generic drug market expansion
- Cost increases due to exchange rate fluctuations
Innovations
2023: Therapeutic Artificial Protein Approved
- Overview
- Obtained approval for innovative artificial protein therapeutic drug, expanding novelty in medical field.
- Impact
- Expected revenue increase from high-value-added products
2022: Clinical Trials Started for New Joint Function Improvement Agent
- Overview
- Initiated clinical trials using new active ingredient for next-generation joint function improvement pharmaceutical.
- Impact
- Strengthened product lineup and improved competitiveness
2021: New Agricultural Chemical Formulation Development Completed
- Overview
- Completed development of new pesticide formulation with enhanced safety and efficacy, preparing for sales launch.
- Impact
- Contributes to revenue expansion in agriculture division
2020: Veterinary Pharmaceutical Line Expanded
- Overview
- Added new antibiotics and supplement products to strengthen the lineup.
- Impact
- Enhanced presence in animal health market
Sustainability
- Promotion of reduced environmental impact in manufacturing processes
- Healthy life expectancy extension activities in collaboration with local communities
- Reduction and proper management of hazardous chemicals
- Expansion of renewable energy adoption
- Continuous improvement in waste recycling rate